Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Annals of Hematology|November 12, 2025
Development of an artificial intelligence-based early diagnostic system for light-chain amyloidosisWei Yan, Jian Chen, Tao He, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemiaDan Li, Tongjuan Li, Zhen Shang, et al.
Clinical Hematology International|August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working GroupWenming Chen, Zhen Cai, Chor Sang Chim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 9, 2024
Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myelomaQiuxia Yu, Di Wang, Zhe Li, et al.
British Journal of Haematology|July 26, 2026
Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma CommitteeXuelin Dou, Aijun Liao, Jun Luo, et al.
Blood|January 29, 2021
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myelomaDi Wang, Jue Wang, Guang Hu, et al.
Clinical Hematology International|May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working groupWenming Chen, Zhen Cai, Chor Sang Chim, et al.
JAMA Oncology|November 7, 2024
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical TrialChunrui Li, Keshu Zhou, Yongxian Hu, et al.
Transplantation and Cellular Therapy|August 23, 2021
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell LymphomasYang Cao, Yi Xiao, Na Wang, et al.
Frontiers in Immunology|June 7, 2022
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt LymphomaJiaying Wu, Yang Cao, Qi Zhang, et al.
Pageof 10